TCL Archive NCI Officials Open To Fine-Tuning Group Budgets As Advocates Chip Away At NCTN’s Façade May 2, 2014
TCL Archive Patient Advocacy: Survivorship Programs Win Funds To form Model Programs December 13, 1996
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
